Chinese trials in first-line NSCLC and colorectal cancer are imminent.
ApexOnco Front Page
Recent articles
Tacti-004 is terminated for futility, and Immutep crashes 89%.
The company plans a pivotal pancreatic cancer trial after seeing two responses in eight patients.
AstraZeneca ended a tie-up with Asher, and then set off on its own.
The FDA has cleared GSK’s drug again, after a no from the advisory committee.
The G12C-selective elironrasib produces a 42% ORR in post-Lumakras/Krazati patients.
The company advances the IDRx-originated KIT inhibitor GSK6042981 into pivotal trials.
Redemption of sorts comes for IO Biotech, but there’s no respite for Summit.
